Literature DB >> 31696232

The technical risks of human gene editing.

Benjamin Davies1.   

Abstract

A recent report from Dr He Jiankui concerning the birth of twin girls harbouring mutations engineered by CRISPR/Cas nucleases has been met with international condemnation. Beside the serious ethical concerns, there are known technical risks associated with CRISPR/Cas gene editing which further raise questions about how these events could have been allowed to occur. Numerous studies have reported unexpected genomic mutation and mosaicism following the use of CRISPR/Cas nucleases, and it is currently unclear how prevalent these disadvantageous events are and how robust and sensitive the strategies to detect these unwanted events may be. Although Dr Jiankui's study appears to have involved certain checks to ascertain these risks, the decision to implant the manipulated embryos, given these unknowns, must nonetheless be considered reckless. Here I review the technical concerns surrounding genome editing and consider the available data from Dr Jiankui in this context. Although the data remains unpublished, preventing a thorough assessment of what was performed, it seems clear that the rationale behind the undertaking was seriously flawed; the procedures involved substantial technical risks which, when added to the serious ethical concerns, fully justify the widespread criticism that the events have received.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CRISPR; Cas9; gene editing; mutagenesis; nuclease

Year:  2019        PMID: 31696232      PMCID: PMC6913216          DOI: 10.1093/humrep/dez162

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  66 in total

1.  Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells.

Authors:  Daesik Kim; Jungeun Kim; Junho K Hur; Kyung Wook Been; Sun-Heui Yoon; Jin-Soo Kim
Journal:  Nat Biotechnol       Date:  2016-06-06       Impact factor: 54.908

2.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

Authors:  Gero Hütter; Daniel Nowak; Maximilian Mossner; Susanne Ganepola; Arne Müssig; Kristina Allers; Thomas Schneider; Jörg Hofmann; Claudia Kücherer; Olga Blau; Igor W Blau; Wolf K Hofmann; Eckhard Thiel
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

3.  Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells.

Authors:  Lokesh Agrawal; Xihua Lu; Jin Qingwen; Zainab VanHorn-Ali; Ioan Vlad Nicolescu; David H McDermott; Philip M Murphy; Ghalib Alkhatib
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

4.  CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury.

Authors:  Mary T Joy; Einor Ben Assayag; Dalia Shabashov-Stone; Sigal Liraz-Zaltsman; Jose Mazzitelli; Marcela Arenas; Nora Abduljawad; Efrat Kliper; Amos D Korczyn; Nikita S Thareja; Efrat L Kesner; Miou Zhou; Shan Huang; Tawnie K Silva; Noomi Katz; Natan M Bornstein; Alcino J Silva; Esther Shohami; S Thomas Carmichael
Journal:  Cell       Date:  2019-02-21       Impact factor: 66.850

5.  Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci.

Authors:  Samuel Lessard; Laurent Francioli; Jessica Alfoldi; Jean-Claude Tardif; Patrick T Ellinor; Daniel G MacArthur; Guillaume Lettre; Stuart H Orkin; Matthew C Canver
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

Review 6.  Genome Editing: Past, Present, and Future.

Authors:  Dana Carroll
Journal:  Yale J Biol Med       Date:  2017-12-19

7.  CCR5 limits cortical viral loads during West Nile virus infection of the central nervous system.

Authors:  Douglas M Durrant; Brian P Daniels; TracyJo Pasieka; Denise Dorsey; Robyn S Klein
Journal:  J Neuroinflammation       Date:  2015-12-15       Impact factor: 8.322

8.  High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.

Authors:  Benjamin P Kleinstiver; Vikram Pattanayak; Michelle S Prew; Shengdar Q Tsai; Nhu T Nguyen; Zongli Zheng; J Keith Joung
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

9.  Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR.

Authors:  Maximilian Haeussler; Kai Schönig; Hélène Eckert; Alexis Eschstruth; Joffrey Mianné; Jean-Baptiste Renaud; Sylvie Schneider-Maunoury; Alena Shkumatava; Lydia Teboul; Jim Kent; Jean-Stephane Joly; Jean-Paul Concordet
Journal:  Genome Biol       Date:  2016-07-05       Impact factor: 13.583

10.  Correction of the Marfan Syndrome Pathogenic FBN1 Mutation by Base Editing in Human Cells and Heterozygous Embryos.

Authors:  Yanting Zeng; Jianan Li; Guanglei Li; Shisheng Huang; Wenxia Yu; Yu Zhang; Dunjin Chen; Jia Chen; Jianqiao Liu; Xingxu Huang
Journal:  Mol Ther       Date:  2018-08-14       Impact factor: 11.454

View more
  4 in total

1.  Cutting Through the "Gray Area": An Analysis of the IBC Regulatory Oversight of Applications of CRISPR Technology in Clinical Research.

Authors:  Westley F Weiss
Journal:  Ther Innov Regul Sci       Date:  2021-05-18       Impact factor: 1.778

Review 2.  Responsible Translational Pathways for Germline Gene Editing?

Authors:  Bryan Cwik
Journal:  Curr Stem Cell Rep       Date:  2020-08-21

Review 3.  Application of CRISPR/Cas Genomic Editing Tools for HIV Therapy: Toward Precise Modifications and Multilevel Protection.

Authors:  Alexandra Maslennikova; Dmitriy Mazurov
Journal:  Front Cell Infect Microbiol       Date:  2022-05-25       Impact factor: 6.073

Review 4.  Genome Editing among Bioethics and Regulatory Practices.

Authors:  Mauro Mandrioli
Journal:  Biomolecules       Date:  2021-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.